Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
DATA GRAPHICS | Data Byte

TSLP mAbs for asthma behind Tezspire

At least eight mAbs in development; two also hit IL-13

By Danielle Golovin, Senior Biopharma Analyst
January 10, 2024 2:30 AM UTC

GSK’s acquistion of Aiolos marks enthusiasm for differentiated TLSP mAbs in the asthma arena.

Just 11 weeks after Aiolos Bio Inc. announced a $245 million series A round to support development of its in-licensed asset for asthma, the start-up’s leadership team has negotiated a $1 billion sale to GSK plc (LSE:GSK; NYSE:GSK)...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Aiolos Bio Inc.

Amgen Inc.

Astrazeneca plc

Biolojic Design Ltd.

Biosion Inc.

Generate Biomedicines Inc.

Gsk plc